AZN.L pharmaceutical industry * Est. 1913
Updated Feb 20, 2026

AstraZeneca_

Cambridge
Market Cap $21.1T
Revenue $24.4B
Employees 70.6K

Stock Overview

AZN.L
$13,600.00
+1.04%
50d: $13,757.72 200d: $11,936.19
Analyst Consensus
Strong_buy
Target $15,277.12
+12.3% upside
21 analysts
52-Week Range
$9,573.50 $15,474.36
Institutional: 56.0% Insider: 0.0%
Market Cap
$210.8B
P/E Ratio
31.2x
Forward P/E
18.3x
EPS
$4.36
Revenue
$58.1B
Rev Growth
+12.0%
Profit Margin
16.2%
Free Cash Flow
$10.0B
Dividend
1.82%
Beta
0.19
Debt/Equity
71.0
Data via Yahoo Finance. Not financial advice. Prices may be delayed.

About

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple next-generation therapies for obesity and type 2 diabetes; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Leadership

Company Details

Industry
pharmaceutical industry
Founded
Headquarters
Cambridge
Stock Ticker
AZN.L
Employees
70,600
Revenue
$24.4B
Market Cap
$21.1T
Wikidata

Frequently Asked Questions

What does AstraZeneca do?

AstraZeneca is a company in the pharmaceutical industry industry. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso

When was AstraZeneca founded?

AstraZeneca was founded in , making it 113 years old.

Where is AstraZeneca headquartered?

AstraZeneca is headquartered in Cambridge.

How many employees does AstraZeneca have?

AstraZeneca employs approximately 70,600 people worldwide.

Is AstraZeneca publicly traded?

Yes, AstraZeneca is a publicly traded company with the stock ticker symbol AZN.L.

What is AstraZeneca's annual revenue?

AstraZeneca has annual revenue of approximately $24.4B.

[AD: 728x90 LEADERBOARD]

More pharmaceutical industry Companies

Browse All